• Loss of $4.8M, up 213.8% from prior period
• Completed acquisition of Galidesivir antiviral program
• Progressed regulatory engagement with FDA on Galidesivir development

Island Pharmaceuticals Limited reported a loss of $4,811,335 for the half-year ended 31 December 2025, up 213.8% from the prior period. The company continued to advance its ISLA-101 drug for dengue fever and expanded its portfolio with the acquisition of the Galidesivir antiviral program from BioCryst Pharmaceuticals. During the period, Island progressed its regulatory strategy for Galidesivir under its open Investigational New Drug (IND) application with the US FDA, including a Type C meeting to seek alignment on utilizing the Animal Rule pathway. The FDA subsequently confirmed that the Animal Rule is an appropriate regulatory pathway for Galidesivir's approval as a countermeasure for Marburg virus, and advised that the program would qualify for a Tropical Disease Priority Review Voucher upon approval. Island also appointed a government affairs firm to strengthen engagement across the US biodefence and health security landscape, and was granted membership to the Medical Countermeasures Coalition to advance US procurement and stockpiling opportunities for Galidesivir.